Aim Concurrent chemoradiotherapy (CRT) is the standard of care for locally advanced, unresectable non-small cell lung carcinoma (NSCLC). The aim of this study was to assess the prognostic value of maximum standardized uptake values (SUV max) in patients with unresectable stage III NSCLC treated with concurrent CRT. Method 18 F-FDG PET-CT scans were obtained before and after treatment in patients with unresectable stage III NSCLC treated with concurrent CRT. To determine the prognostic value of SU-V max of the primary tumor (PT), univariate and multivariate Cox regression model were carried out. Results Between January 2008 and December 2013, this study included 43 patients (median age 56 years, 95% male). Univariate analysis showed that having a high post-treatment PT-SU-V max was associated with a higher risk of death and having a high post-treatment PT-SUV max with a higher risk of disease recurrence. Multivariate analysis showed that having a low post-treatment PT-SUV max (cut off 3.9) was associated with longer overall and progression free survival (HR 8.55, 95% CI; 2.56-28.55, p=0.000 and HR 2.854, 95% CI; 1.43-5.67, p=0.003, respectively). Conclusion Post-treatment PT-SUV max may be an independent prognostic factor in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy.
Rami-Porta R, Crowley J, Goldstraw P, P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;4–9.
2.
Vokes E. Optimal therapy for unresectable stage III non-smallcell lung cancer. J Clin Oncol. 2005;5853–5.
3.
Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 1999;2692–9.
4.
Berghmans T, Paesmans M, Sculier J. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol. 2011;127–38.
5.
Kligerman S, Digumarthy S. Staging of non-small cell lung cancer using integrated PET/CT. Am J Roentgenol. 2009;1203–11.
6.
Pieterman R, Van Putten J, Meuzelaar J, Mooyaart E, Vaalburg W, Koeter G. Preoperative staging of nonsmall-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;254–61.
7.
Toloza E, Harpole L, Mccrory D. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;137–46.
8.
Chen J, Huang T, Cheng Y, Chang H, Tzao C, Huang W, et al. Prognostic value of 18-FDG uptake in early stage NSCLC. Thorac Cardiovasc Surg. 2009;413–6.
9.
Vesselle H, Grierson J, Muzi M, Pugsley J, Schmidt R, Rabinowitz P, et al. In vivo validation of 3’deoxy-3’-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;3315–23.
10.
Usuda K, Saito Y, Sagawa M, Sato M, Kanma K, Takahash S, et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer. 1994;2239–44.
11.
Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected nonsmall cell lung cancer. J Nucl Med. 2002;39–45.
12.
Hoang J, Hoagland L, Coleman R, Coan A, Herndon J, Patz E. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol. 2008;1459–64.
13.
Lee H, Lee K, Park J, Han J, Kim B, Kwon O, et al. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes. Acad Radiol. 2012;440–5.
14.
Jeong H, Min J, Park J, Chung J, Kim B, Jeong J, et al. Determination of the prognostic value of [18F] fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun. 2002;865–70.
15.
Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte J, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer. Update of a systematic review and meta analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2010;612–9.
16.
Kaira K, Endo M, Asakura K, Tsuya A, Nakamura Y, Naito T, et al. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer. Ann Nucl Med. 2010;697–705.
17.
Usmanij E, De Geus-Oei L, Troost E, Peters-Bax L, Van Der Heijden E, Kaanders J, et al. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med. 2013;1528–34.
18.
Kim S, Oh S, Kim J, Kim K, Kim Y. Prediction of response by FDG PET early during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. Radiat Oncol J. 2014;231–7.
19.
Paesmans M, Garcia C, Wong O, Patz C, Jr E, Komaki R, et al. Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariatepooled analysis of individual data. Eur Respir J. 2015;1751–61.
20.
Macmanus M, Hicks R, Matthews J, Mckenzie A, Rischin D, Salminen E, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;1285–92.
21.
Guerra L, Gladish J, Komaki G, Gomez R, Zhuang D, Liao Y, et al. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced nonsmall cell lung cancer. J Nucl Med. 2012;225–33.
22.
Machtay M, Duan F, Siegel B, Snyder B, Gorelick J, Reddin J, et al. Prediction of survival by [18F] fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013;3823–30.
23.
Xiang Z, Erasmus J, Komaki R, Cox J, Chang J. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiat Oncol. 2012;144–52.
24.
Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, et al. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 2002;
25.
Decoster L, Schallier D, Everaert H, Nieboer K, Meysman M, Neyns B, et al. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography ((18) FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2008;55–61.
26.
Dehdashti F, Mortimer J, Trinkaus K, Naughton M, Ellis M, Katzenellenbogen J. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2008;509–17.
27.
Connell C, Corry J, Milner A, Hogg A, Hicks R, Rischin D, et al. Clinical impact of, and prognostic stratification by, F-18FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007;986–95.
28.
Schwarz J, Siegel B, Dehdashti F, Myerson R, Fleshman J, Grigsby P. Tumor response and survival predicted by post-therapy FDG PET/ CT in anal cancer. Int J Rad Oncol Biol Phys. 2008;180–6.
29.
Atkins C. Overestimation of the prognostic significance of SUV measurement by positron emission tomography for non-small-cell lung cancer. J Clin Oncol. 2005;6799–800.
30.
Brundage M, Davies D, Mackillop W. Prognostic fac tors in non-small cell lung cancer-a decade of progress. Chest. 2002;1037–57.
31.
Dhital K, Saunders C, Seed P, Doherty O, Dussek M, J. F-18]fluorodeoxyglu cose positron emission tomography and its prognostic value in lung cancer. Eur J Cardio Thoracic Surg. 2000;425–8.
32.
Eschmann S, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. Is standardised F-18-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging. 2006;263–9.
33.
Weber W, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;2651–7.
34.
Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;1136–43.
35.
Ikushima H, Dong L, Erasmus J, Allen P, Mcaleer M, Zhuang Y, et al. Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy. J Radiat Res. 2010;465–71.
36.
Vesselle H, Freeman J, Wiens L, Stern J, Nguyen H, Hawes S, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res. 2007;3255–63.
37.
Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Omagari J, Akashi Y, et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bron chogenic carcinoma. Ann Nucl Med. 1996;193–200.
38.
Kim Y, Lee M, Kim S, Kim I, Kim Y, Park J, et al. Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (stage III and IV) non-small cell lung cancer. Neoplasma. 2010;241–6.
39.
Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J. Prognostic stratification of stage IIIAN2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol. 2008;1128–34.
40.
Ryu J, Choi N, Fischman A, Lynch T, Mathisen D. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer. 2002;179–87.
41.
Song S, Kim J, Ryu J, Lee G, Kim S, Park S, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Rad Oncol Biol Phys. 2005;1053–9.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
